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Pulmonary ﬁbrosis affects millions worldwide and, even though there has been a signiﬁcant investment
in understanding the processes involved in wound healing and maladaptive repair, a complete under-
standing of the mechanisms responsible for lung ﬁbrogenesis eludes us, and interventions capable of
reversing or halting disease progression are not available. Pulmonary ﬁbrosis is characterized by the
excessive expression and uncontrolled deposition of extracellular matrix (ECM) proteins resulting in
erosion of the tissue structure. Initially considered an ‘end-stage’ process elicited after injury, these
events are now considered pathogenic and are believed to contribute to the course of the disease. By
interacting with integrins capable of signal transduction and by inﬂuencing tissue mechanics, ECM
proteins modulate processes ranging from cell adhesion and migration to differentiation and growth
factor expression. In doing so, ECM proteins help orchestrate complex developmental processes and
maintain tissue homeostasis. However, poorly controlled deposition of ECM proteins promotes in-
ﬂammation, ﬁbroproliferation, and aberrant differentiation of cells, and has been implicated in the pa-
thogenesis of pulmonary ﬁbrosis, atherosclerosis and cancer. Considering their vital functions, ECM
proteins are the target of investigation, and oxidation–reduction (redox) reactions have emerged as
important regulators of the ECM. Oxidative stress invariably accompanies lung disease and promotes
ECM expression directly or through the overproduction of pro-ﬁbrotic growth factors, while affecting
integrin binding and activation. In vitro and in vivo investigations point to redox reactions as targets for
intervention in pulmonary ﬁbrosis and related disorders, but studies in humans have been disappointing
probably due to the narrow impact of the interventions tested, and our poor understanding of the factors
that regulate these complex reactions. This review is not meant to provide a comprehensive review of
this ﬁeld, but rather to highlight what has been learned and to raise interest in this area in need of much
attention.
& 2016 Published by Elsevier B.V. This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
Lung ﬁbrosis is characterized by, among other things, the ef-
facement of the original architecture of the lung due to excessive
expression and deposition of the extracellular matrix (ECM) [1]. In
normal lungs, this acellular substance is a complex admixture of
glycoproteins, collagens, and polysaccharides neatly assembled so
as to maintain tissue integrity and to separate epidermal and
mesenchymal cell layers in tissues [2]. In injured lungs, however,
inﬂammation, oxidative stress, and other events drive the ex-
pression and turnover of ECM proteins. In most cases, this process
is regulated and is inhibited once the injuring agent is eliminated.n open access article under the CC
iversity of Louisville, Health
ory Care Building, 3rd ﬂoor-
.Yet, on occasion, this process remains activated leading to thick-
ening of the interstitium followed by permanent obliterations of
the alveolar spaces and loss of lung function [3] (Fig. 1). These
events underlie ﬁbrosing lung disorders affecting millions
worldwide.
Cells differ in their capacity for producing, secreting, and as-
sembling ECM, and its composition differs amongst organs and
between organ compartments. The ECM was initially considered to
be an inert substance providing scaffold for the adhesion of cells
and for their organization into complex organs. In the early 1980s,
however, a better appreciation of the true role of the ECM began to
emerge with the discovery of a family of cell surface adhesion
receptors termed integrins [4]. Integrin activation by ligand
binding to ECM proteins triggers diverse intracellular signals
capable of inﬂuencing gene expression [5]. This early work laid the
foundation for our current understanding that cell functions are
greatly inﬂuenced by the composition of their surrounding ECMBY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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Fig. 1. Development, tissue homeostasis, and response to injury are dependent on ECM expression and deposition. ECM expression and turnover are tightly controlled
during organ development and during adulthood. Tissue injury triggers inﬂammation, clotting, redox stress, and regulated expression and degradation of the ECM. In
general, elimination of the injurious agents is followed by ‘turning off’ this wound healing response resulting in inhibition of ECM expression and, ultimately, a return to the
original tissue structure and function (Adaptive Repair). However, on occasion, injury triggers an exuberant response characterized by uncontrolled ECM expression and
turnover leading to increased stiffness of the tissue and eradication of the original tissue architecture leading to loss of function (Maladaptive Repair). These events are
greatly inﬂuenced by genetics and environmental exposures. Uncontrolled generation of reactive oxidant species (ROS) is thought to contribute to maladaptive repair, in part,
by promoting aberrant ECM expression and ﬁbroproliferation.
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their surface. Moreover, ECM proteins are the main contributors to
tissue stiffness, which also inﬂuences cell behavior [6].
It is well documented that ECM proteins play roles in regulating
important cell functions such as adhesion, migration, and differ-
entiation as well as in complex processes like tissue morphogen-
esis and wound healing [7,8]. However, the exact roles ECM pro-
teins play in cellular and tissue homeostasis in human health and
disease remain incompletely elucidated mainly because in vitro
models fail to reﬂect the complex nature of in vivo ECM, because
genetically-engineered animals with knockout mutations of genes
coding for ECM and matrix-binding integrin receptors are often
embryonic lethal [9], and because of the complex, robust and in-
soluble nature of assembled ECM which makes their study ardu-
ous even in the most experienced hands [10]. However, these
challenges are being partially overcome by the emergence of new
experimental models (e.g., organ decellularization) and novel ap-
proaches to genetic targeting of proteins [11]. Together, these
technologies have helped generate data about the lung ‘matri-
some’, thereby adding to the overwhelming literature available in
support of the role of ECM proteins in embryogenesis and tissue
homeostasis after birth, as well as in the development of disorders
ranging from atherosclerosis and kidney disease to rheumatoid
arthritis and cancer [8,12,13].
In lung, ECM proteins have been implicated in lung branching
morphogenesis, vasculogenesis, and alveolar maturation during
development, as well as in tissue repair after injury [14,15].
However, ECM proteins have also implicated in pathologic pro-
cesses leading to acute and chronic pulmonary disorders such as
asthma, acute lung injury, and idiopathic pulmonary ﬁbrosis (IPF)
[16–18]. Considering the above, and the fact that essentially all
pulmonary disorders are associated with alterations in the ex-
pression, deposition and turnover of ECM proteins, it is no surprisethat understanding the factors that regulate ECM-dependent
events in lung has remained a focus of attention for over two
decades.
Oxidants and redox reactions have been found to inﬂuence
ECM expression and turnover, and these appear to be important
physiological processes relevant to health, but also to diseased
states such as lung ﬁbrogenesis [19]. Patients with ﬁbrosing lung
disorders manifest evidence of oxidative stress [20–23], which
triggers intracellular signals that stimulate ﬁbroproliferation and
the expression of pro-ﬁbrotic factors [24], while interventions
targeting the oxidant-anti-oxidant balance ameliorate progression
of ﬁbrosis in animal models of lung injury [25,26]. Together, these
observations strongly implicate oxidative stress in the pathogen-
esis of ﬁbrosing lung disorders, and even though its role as a target
for intervention in lung ﬁbrosis remains controversial [27], the
exploration of redox as an important modulator of ECM produc-
tion, modiﬁcation, function, and recognition by cells is justiﬁed.
Excellent reviews have been published addressing aspects of this
area of investigation [28–30]. Thus, we will focus on the impact of
redox reactions on the lung ECM considering that this organ is
exposed to higher levels of oxygen than other tissues. A descrip-
tion of the lung ECM and its functions in lung development and in
injury and repair will be followed by a discussion of redox reac-
tions considered to inﬂuence these events. Finally, information
will be provided that provide strong evidence supporting the
concept that ECM protein expression, turnover and recognition are
redox-dependent events.2. Role of lung ECM
The importance of ECM proteins in multicellular organisms is
highlighted by their function as a multi-dimensional structural
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vate signaling cell surface receptors, and regulate cell proliferation
and differentiation, among other processes [31,32]. Together with
soluble factors, these functions enable ECM proteins to orchestrate
tissue morphogenesis, differentiation, and homeostasis [7,8],
processes critical for the adequate development and repair of all
major organs, including the lung. In the embryonic lung, branching
morphogenesis, alveolar septation, and terminal differentiation of
the various cells of the lung are all dependent on proper signals
derived from the ECM [7,14]. The maintenance of cell polarity and
the regulation of cell functions by the epithelium are also highly
dependent on the ECM, including its three-dimensional and to-
pographic cues [33].
ECM deposition, remodeling, and resorption are dynamic pro-
cesses that are precisely controlled during normal lung develop-
ment, homeostasis, and tissue repair. Since the primary function of
the adult lung is gas exchange, the specialized structure and
composition of the pulmonary ECM is designed to facilitate this
function. In the upper airways, the ECM is specialized for struc-
tural support in order to prevent airway collapse. However, in the
lower airways, the ECM forms a specialized basement membrane
layer made from many different ECM proteins such as chondroitin
sulfate proteoglycans, heparan sulfate proteoglycans, entactin, la-
minins [34,35], ﬁbronectins [36], collagens [37] and glycosami-
noglycans [38]. These ECM components affect bronchial epithelial
cell attachment [39] and migration [40] as well as the differ-
entiation of cells lining the alveolus. The latter is best depicted by
the observation that isolated type II airway epithelial cells quickly
lose their specialized phenotype if not cultured on the proper
ECM. In contrast, when cultured on three-dimensional collagen gel
matrices, these cells proliferate and form branching structures that
contain lumens lined by both ﬂattened and cuboidal epithelium
[41], while expressing surfactant-associated proteins SP-A, SP-B,
and SP-C [42,43]. Claudin-dependent cell–cell interactions re-
sponsible for lung epithelial cell monolayer formation and control
of permeability are also affected by the ECM [44]. Lung develop-
ment is clearly inﬂuenced by ECM proteins and redox reactions,
but how these events relate to each other remains unclear [160].
In contrast to the uninjured developing and adult lung, the
diseased lung shows exaggerated and uncontrolled expression,
deposition and turnover of collagens and other ECM proteins
leading to, at the very least, qualitative alterations in the compo-
sition of the ECM, and at worse, disruption of organ architecture
with loss of tissue function [1,3]. Remodeling is triggered early
after tissue injury, and could be dissociated from (and therefore
controlled by processes other than) inﬂammation [45]. Recent
studies have further emphasized the role of ECM proteins in lung
injury and repair. For example, normal ﬁbroblasts cultured atop
human ﬁbrotic lungs after decellularization manifest changes in
phenotype characterized by increased expression of myoﬁbroblast
markers [46]. Moreover, animals deﬁcient in a splicing variant of
ﬁbronectin termed ﬁbronectin EDA, a matrix glycoprotein highly
expressed after injury and implicated in tissue repair, show pro-
tection against ﬁbrosis in the bleomycin model [47].
In addition to the above, ECM proteins have been found to af-
fect immune cell activation and cytokine expression, serve as a
reservoir for growth factors, and inﬂuence autophagy [48,49].
More recently, attention has been given to the role of ECM proteins
in controlling tissue stiffness and how this impacts cellular beha-
vior. The stiffness of the lung increases with enhanced deposition
of collagens during tissue ﬁbrosis, and this mechanical stimulus is
sufﬁcient to exert changes in cell function that further drive ﬁ-
brogenesis [6,50].3. Redox reactions
Reduction and oxidation reactions (also termed redox reac-
tions) have profound effects on biological processes. The oxidation
reactions that have received the most attention with respect to
human health are those arising from the interaction of an oxygen
metabolite with biological molecules. Much has been learned over
the last several decades about the conditions that lead to the
formation of reactive oxygen metabolites and the association of
disease processes with levels of speciﬁc oxidation products.
Successive one-electron reductions of molecular oxygen (O2)
yield the superoxide anion radical (O2), the non-radical species
hydrogen peroxide (H2O2), the extremely reactive hydroxyl radical
(OH), and, ﬁnally, water (H2O). The most abundant source of
superoxide is leakage of incompletely-reduced oxygen from the
mitochondrial electron transport chain [51]. Superoxide can
spontaneously dismutate to produce O2 and H2O2, but this reac-
tion is greatly accelerated by superoxide dismutases (SODs). The
H2O2 formed from these (and other) enzymes is more stable than
superoxide, and, because it is uncharged, it is able to diffuse
through biological membranes. Enzymes such as catalase, glu-
tathione peroxidases, and peroxiredoxins catalyze the 2-electron
reduction of H2O2 to H2O, but there are no enzymes that catalyze
its 1-electron reduction to OH. Rather, the hydroxylradical is
formed non-enzymatically in the presence of unbound transition
metals. Once formed, OH is so reactive that it can remove an
electron from the ﬁrst molecule it encounters. Clearly, such in-
discriminant reactivity would disrupt normal cellular functions.
Fortunately, free transition metals are kept at extremely low levels
under normal conditions.
An observable consequence of augmented production of re-
active oxygen metabolites is an increase in the number of oxida-
tive modiﬁcations to cellular and extracellular constituents such as
proteins, DNA, and lipids. Stable (irreversible) modiﬁcations make
good biomarkers because they accumulate in cells or tissues ex-
periencing increased rates of oxidant production and, therefore,
provide a measure of the overall oxidant burden. Oxidation pro-
ducts of lipids (e.g., isoprostanes), proteins (e.g., diTyrosine), DNA
(e.g., 8-oxo-deoxyguanosine) and sugars (e.g., advanced glycation
end products, AGE) have all been correlated with speciﬁc patho-
logical processes [52–56]. In addition, these biomarkers can
sometimes have signaling roles. For example, isoprostanes can
activate the thrombane X receptor [52,57] and AGE can bind to
receptors of AGE (RAGE) [58]. Irreversible oxidative modiﬁcations
of macromolecules also serve as signals for degradation or repair.
For example, tyrosine cross-links (diTyrosine) mark proteins for
turnover [59], and oxidized nucleotides trigger DNA repair [60].
Oxidant production is not always accidental or harmful. For
example, superoxide and H2O2 are produced as signaling mole-
cules in response to growth factor stimulation and are important
in immunity [60,61]. A major source of oxidants used for signaling
purposes is the NADPH oxidase (Nox) family of enzymes. These
enzymes catalyze the transfer of electrons from NADPH to O2 to
produce superoxide or H2O2. The founding member of this family,
Nox2, was discovered as a key component of the respiratory burst
that enables macrophages and other cells of the innate immune
system to convert oxygen to cytotoxic agents to be used in host
defense [62]. Other family members have been identiﬁed with
different tissue expression levels and subcellular distributions
whose main functions appear to be related to signaling rather than
host defense. All cell types found in the lung express at least one
isoform of Nox3 [63].
Reversibility is a major characteristic of oxidative modiﬁcations
that are used for signaling purposes. Targets that are irreversibly
modiﬁed accumulate and need to be replaced if they serve a vital
cellular process. Reversible modiﬁcations, on the other hand,
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sulfur atom associated with the amino acid cysteine, for example,
can exist in multiple stable redox states. Most intracellular cy-
steines are found in the reduced or thiol form (SH), but can be
oxidized to a sulfenic acid (SOH) or a disulﬁde (SS). These are
equivalent 2-electron oxidations, and can be reduced back to the
thiol form using 2 electrons from NADPH. The target cysteines can
be the free amino acid, in the tripeptide glutathione (GSH), or
found as one of the amino acids comprising all cellular proteins
[64]. Different enzymes catalyze the transfer of electrons from
NADPH depending on which of these forms of cysteine has been
oxidized. These events may affect the oxidation of thiol disulﬁde
couples. Redox couples are comprised of 2 chemical species that
are interconvertible via exchange of electrons. Cysteine (Cys) and
its disulﬁde form, cystine (CySS) constitute a redox couple, as does
GSH and its disulﬁde (GSSG). Under conditions where the rate of
oxidation is increased, the proportion of the couple in the oxidized
form will increase and its redox potential will change. The redox
potential of the Cys/CySS or GSH/GSSG redox couples is best de-
scribed by the Nernst equation [64] because it takes into account
the concentrations of the components as well as the stoichiometry
of thiol–disulﬁde exchange reactions such as these
(2Cys2CySSþ2eþ2Hþ). Thus, the Cys concentration is squared
in the equilibrium expression. While redox couples are not at
equilibrium in biological systems, the Eh value from the Nernst
equation nonetheless provides the most comprehensive numerical
representation of the redox potential under a given set of condi-
tions. For this reason, Eh values are often referred to as expressing
the redox state rather than the redox potential to emphasize that
these values are derived from steady state concentrations instead
of equilibrium concentrations. Eh values allow comparisons be-
tween different redox couples. For example, the Eh value for the
Cys/CySS redox couple in human plasma (Eh Cys/CySS) is normally
about 80 mV, whereas the Eh GSH/GSSG for human plasma is
about 137 mV [65]. Clearly, these 2 redox couples are not in
equilibrium with each other in human plasma, suggesting that
they are independently regulated.
The Cys/CySS redox couple is the predominant thiol–disulﬁde
couple in plasma. This is in contrast with intracellular spaces,
where GSH/GSSG predominates. Plasma Eh Cys/CySS becomes
more oxidizing (less negative) with age, cigarette smoking, type
2 diabetes and cardiovascular disease [66]. Nutrition also affects
plasma Eh Cys/CySS [67]. These events have dramatic effects on
cells. For example, culturing Caco-2 cells in media with an oxi-
dizing Eh Cys/CySS stimulates their proliferation through activa-
tion of the epidermal growth factor receptor in a metalloprotei-
nase-dependent manner [68,69]. The effect could be blocked by
adding a cell membrane-impermeable thiol-reactive maleimide,
suggesting that the effect was dependent on extracellular thiols. In
another example, endothelial cells cultured in media with oxidized
Eh Cys/CySS showed increased H2O2 production and expression of
adhesion molecules in concert with a decrease in extracellular
membrane protein thiol content [70]. Interestingly, cells grown in
culture will condition the medium in which they are growing such
that the redox state of Cys/CySS stabilizes at 80 mV, the same
value as seen in human plasma [71,72]. Thus, the redox state of a
speciﬁc redox couple reﬂects the summation of effects on rates of
oxidation and rates of reduction, and this redox state can be
sensed by cells leading to changes in cell behavior.
Data have emerged implicating oxidative stress as a pathogenic
factor in tissue ﬁbrosis. In humans with ﬁbrosing lung disorders,
deﬁciencies in anti-oxidant defenses have long been identiﬁed. For
example, investigators studied 16 IPF and 15 healthy non-smoking
subjects, and found that sputum glutathione (GSH) was decreased
more than four-fold in IPF patients [20]. Plasma GSH levels were
also lower in IPF. Interestingly, in IPF patients, there was aborderline correlation of sputum GSH levels with disease pro-
gression and lung function impairment in IPF patients. Others
studied the metabolism of GSH and superoxide anion production
of whole blood in 14 IPF patients and 12 healthy subjects [23].
They found that the total amount of GSH in the blood of IPF pa-
tients did not differ from the controls, but the amount of GSH in
the oxidized disulﬁde (GSSG) and the ratio of GSSG to total GSH in
blood signiﬁcantly increased in IPF patients. Also, the production
and generation of superoxide anions by blood were greater in IPF
than in normal subjects; this correlated with the GSSG/GSH ratio.
Yet others studied the alveolar lining ﬂuid of newly diagnosed IPF
patients and reported signiﬁcantly lower levels of total GSH when
compared to sarcoid patients and controls [22]. In this study, GSH
levels increased after treatment. This underlying redox state can
be enhanced by oxygen radicals produced by inﬂammatory cells
[73] and may help maintain the pro-ﬁbrotic phenotype of lung
ﬁbroblasts [74]. Together, these and other observations point to
redox reactions as an important pathogenic mechanism in lung
ﬁbrosis. However, simple interventions (e.g., N-acetylcysteine)
designed solely to improve GSH levels in lung have proven in-
effective in some populations suggesting that redox reactions in
lung ﬁbrosis are complex and inﬂuenced by many factors includ-
ing genetics and, therefore, will require further investigation.4. Redox – dependent ECM expression
Redox reactions can stimulate ECM expression via at least three
mechanisms of action: 1) activation of redox-signaling cascades in
response to pro-ﬁbrotic growth factors, 2) activation of tran-
scription factors and/or epigenetic events that drive ECM gene
transcription, and 3) oxidation of the redox potential of thiol dis-
ulﬁde couples.
4.1. Pro-ﬁbrotic effects of transforming growth factor-beta (TGFβ)
are dependent on redox signaling cascades
Of the many growth factors capable of stimulating ECM pro-
duction, TGFβ is considered the ‘master switch’ for lung ﬁbrosis; it
promotes ECM expression directly through activation of TGFβ re-
ceptors and upregulation of signals involving the Smads and mi-
togen activated protein kinase pathways [75]. TGFβ also promotes
the expression of other pro-ﬁbrotic growth factors such as con-
nective tissue growth factor (CTGF), which can amplify the ﬁbrotic
response [76]. It also acts via matrix metalloproteinases (MMPs)
and the upregulation of matrix-binding integrins, which can, in
turn, activate TGFβ [77,78]. Through these activities, TGFβ pro-
motes the proliferation of ﬁbroblasts, considered effector cells in
tissue ﬁbrosis, as well as their production of matrix glycoproteins
like ﬁbronectins, ﬁbrillar collagens (e.g., collagens type I and III),
and proteoglycans, among other ECM proteins.
Interestingly, TGFβ represents the best example of redox-de-
pendent growth factor-induced ECM expression since many of its
pro-ﬁbrotic effects are dependent on Nox-4 and the generation of
reactive oxygen species (Fig. 2). Treatment with siRNA against
NOX4 suppressed TGFβ-induced expression of ﬁbronectin, col-
lagen I, α-smooth muscle actin, and connective tissue growth
factor in cardiac ﬁbroblasts [79]. Similarly, chemical inhibition of
Nox-4 suppressed ECM production and epithelial–mesenchymal
transition in renal tubular epithelial cells [80,81]. Furthermore,
TGFβ stimulation of collagen synthesis and myoﬁbroblast trans-
differentiation is inhibited by a scavenger of superoxide and H2O2,
and by a dominant negative form of Nox 4 [82]. Similar events
have been noted in fetal lung mesenchymal cells [83], pulmonary
ﬁbroblasts [84], kidney ﬁbroblasts [85] and liver stellate cells [86].
There also appears to be a reciprocal interaction between TGFβ
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Fig. 2. ROS-dependent TGFβ activation and function. TGFβ can be produced by cells
or liberated from ECM reservoirs during tissue remodeling. Its latent form is con-
verted into active TGFβ through the actions of MMPs or ROS. Once activated, TGFβ
interacts with cell surface receptors leading to the activation of Nox-4 and the
generation of ROS. In turn, ROS promotes target gene expression through effects on
protein kinases and transcription factors.
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this appears to be downstream of Smad 2/3 activation [91].
These studies strongly suggest that Nox-4 modulates many of
the pro-ﬁbrotic actions of TGFβ in vitro. Studies in animal models
of lung ﬁbrosis suggest that these mechanisms of action are also
relevant in vivo. For example, bleomycin-induced ﬁbrosis was
suppressed with tracheal administration of Nox-4 siRNA [92]. Si-
milar observations were made in Nox-4 knockout mice [93],
whereas knockdown of Nox-2 was not as effective [94].
TGFβ not only promotes oxidative stress, but it also decreases
the expression of several anti-oxidant enzymes. For example, TGFβ
inhibits the mRNA expression and activity of glutathione perox-
idase 1 and catalase in hamster pancreatic cell lines [95], and
suppresses the expression of superoxide dismutase-1 (SOD1) and
-2 (SOD2) and catalase in cultured rat hepatocytes and in airway
smooth muscle cells [96,97]. Interestingly, oxidation of latency-
associated protein or MMPs can facilitate the activation of latent
TGFβ [98,99], providing a means for continued TGFβ activity under
conditions of oxidative stress. Thus, the actions of TGFβ, the pro-
ﬁbrotic growth factor most implicated in tissue ﬁbrosis, appear to
be tightly linked to redox reactions.
4.2. Redox-dependent ECM expression via activation of transcription
factors and/or epigenetic events
Redox reactions are known to affect gene transcription through
effects on transcription factor activation or via epigenetic events.
For example, redox reactions are well-known to inﬂuence fos and
jun DNA binding [100]. A member of this family, Activator Protein-
1 (AP-1), a transcription factor needed for the expression of alpha2
(I) collagen and ﬁbronectin in response to TGFβ [101,102]. MMPs
are also affected by these mechanisms. For example, age-depen-
dent increases in MMP-1 are dependent on the generation of re-
active oxidant species, which appears to occur through regulation
of MMP-1 gene transcription as well as chromatin remodeling
affecting gene activation [103]. H2O2 inactivates histone deacety-
lase-2 (HDAC-2), thereby maintaining the MMP-1 promoter ac-
cessible to transcription factors such as c-Fos, c-Jun, and Ets-1.
These and other transcriptions factors may also be activated by
redox-sensitive pathways including MAPK activation [104,105].Thus, ECM expression and MMP production appear dependent on
redox reactions affecting transcription factor activation and epi-
genetic changes. This is intriguing considering emerging data
implicating aberrant control of gene expression through epige-
netic mechanisms in the setting of aging and IPF [106].
4.3. Redox potential – mediated ECM expression
Aging, malnutrition, alcohol abuse, cigarette smoking, and
cancer, among other disorders, are associated with oxidation of
thiol disulﬁde couples [66,67]. Although how this process pro-
motes ECM expression in lung remains incompletely elucidated,
several observations have provided important new insight into
this area. Fibroblast cell lines (NIH 3T3 ﬁbroblasts) and primary
murine lung ﬁbroblasts cultured in media with oxidized Eh Cys/
CySS (41 mV) show increased proliferation as well as increased
expression of ﬁbronectin when compared to cells cultured in
normal (81 mV) and reduced (105 mV) Eh Cys/CySS [24].
These events are associated with increased expression of α-
smooth muscle actin suggesting concomitant myoﬁbroblast
transdifferentiation. Interestingly, the expression of these pro-ﬁ-
brotic markers was inhibited by anti-TGFβ antibodies as well as
chemical blockers of TGFβ receptor function suggesting a critical
role for TGFβ in mediating redox potential – mediated ECM ex-
pression [24].
Oxidation of the extracellular redox potential also stimulates
the expression of integrins and other cell adhesion molecules in-
cluding ICAM-1, VCAM-1, P-selectin, and E-selectin in vitro [107].
However, few in vivo studies are available regarding the role of
redox potential of thiol disulﬁde couples in lung ﬁbrosis. Of re-
levance, mice exposed to bleomycin, a well-known model of lung
ﬁbrosis, develop oxidation of the Eh Cys/CySS and Eh GSH/GSSG
[108]. Furthermore, oxidation of Eh Cys/CySS correlates with in-
creased pro-inﬂammatory cytokine levels in these animals [109].
Finally, preliminary studies suggest that patients with IPF also
manifest oxidation of Eh Cys/CySS (personal observations).5. Redox-dependent ECM modiﬁcation
Redox reactions can promote ECM modiﬁcations, which may
alter their interactions with each other, with cells, and with
growth factors. In general, ECM proteins can be modiﬁed by en-
zymatic digestion or by oxidation. Of the cell-derived proteinases
capable of ECM degradation, MMPs are some of the best studied.
MMPs are highly expressed in inﬂammatory conditions and have
been implicated in many pulmonary disorders ranging from
asthma and other obstructive airways disorders to acute lung in-
jury and idiopathic pulmonary ﬁbrosis [110]. Most MMPs are re-
leased from cells as ‘pro-enzymes’, which are activated by pro-
teolysis of a cysteine-zinc prodomain, called a ‘cysteine switch’
[110]. Once activated, these proteinases can act on many ECM
substrates including collagens I, II, III, V, VII, X, gelatin, elastin, ﬁ-
bronectin, proteoglycans, and basement membrane components
such as collagen IV and laminins. MMPs can also target other
MMPs as well as soluble growth factors including latent TGFβ and
pro-TNFα [110,111], thereby affecting their function. The activity of
MMPs is regulated by tissue inhibitors of MMPs (TIMPs) in a 1:1
stoichiometric fashion; thus, their activity is dependent on the
relative concentration of MMPs and TIMPs [112]
Oxidation is another important mechanism of ECM modiﬁca-
tion (Fig. 3). Most oxidants generated within cells cannot diffuse
out into the extracellular space and, consequently, have limited
effect on the ECM [113]. However, oxidants formed extracellularly
may gain access to the ECM and modify its components to the
point of altering their impact on cells. This is particularly relevant
ROS
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Fig. 3. ROS effects on ECM-integrin interactions and signaling. Cells interact with
ECM proteins via integrins that cluster at the cell surface in focal adhesion com-
plexes containing signaling adapter molecules and cytoskeletal structures. Activa-
tion of integrins results in biochemical signals that inﬂuence differential gene ex-
pression. By integrating the extracellular insoluble ECM with the intracellular cy-
toskeleton, integrins transmit mechanical signals (mechanotransduction) that also
inﬂuence gene expression. Ultimately, cellular responses to ECM proteins are de-
pendent on the composition and stiffness of the ECM, which can be altered by
MMP- or ROS-mediated degradation or by ROS-mediated oxidation. Integrin acti-
vation by ECM can be affected by ROS through effects on cysteines contained within
the α and β subunits of integrins leading to conformational changes in the re-
ceptors. Tissue remodeling after injury resulting from the activity of MMPs and ROS
can liberate growth factors from their ECM reservoir. One growth factor with pro-
ﬁbrotic activity is TGFβ, which can interact with surface receptors leading to Nox-4
activation (and locations to focal adhesion complexes) and further generation of
ROS.
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activated neutrophils, macrophages, and eosinophils, among other
immune cells. These cells assemble Nox complexes on their
membranes and produce superoxide radicals, which are released
extracellularly and can be catalyzed into hydrogen peroxide by
extracellular superoxide dismutases, thereby generating more
oxidants. Activated neutrophils, monocytes and macrophages can
also release myeloperoxidase, an enzyme that binds to ECM pro-
teins and localizes damage to speciﬁc sites. Furthermore, the
resting Fe3þ form of myeloperoxidase reacts with hydrogen per-
oxide and generates more oxidants [114–116]. Eosinophils produce
eosinophil peroxidase with similar capabilities. Chloramines, bro-
mamines and reactive aldehydes can cross membranes as well and
promote further generation of oxidant radicals [117].
The production of radicals through the aforementioned reac-
tions can lead to carbohydrate oxidation on glycosaminoglycans
yielding α-hydroxyalkyl radicals capable of catalyzing reactions
with nearby C–OH and C–OR bonds [118]. This can result in gly-
cosidic bond cleavage and the formation of peroxyl radicals, which
can trigger further chain reactions. These and related events result
in the oxidation of collagens, elastin, ﬁbronectin, laminin and
glycosaminoglycans [119]. Glycosaminoglycans are particularly
susceptible since peroxynitrite can modify their core protein and
heparan sulfate chains as has been document for perlecan, a
basement membrane-speciﬁc heparin sulfate proteoglycan [120].
Polyanionic molecules like heparan sulfate proteoglycans can bind
cationic proteins and transition metals, thereby serving as sub-
strates for metal-catalyzed redox events.
One can envision how these events may inﬂuence ECM reg-
ulation of cell adhesion and signaling, interactions with growth
factors, epithelial and endothelial cell permeability, and other
cellular processes, yet formal studies providing insight into these
events are only fairly recent [121,122]. Oxidative modiﬁcations of
the protein core of perlecan, for example, inﬂuence the adhesionof endothelial cells [123]. Oxidation events can also destabilize
interactions between ECM components and growth factors. For
example, FGF2 binds to perlecan via its heparin sulfates, and
modiﬁcation of perlecan by oxidation may render FGF2 susceptible
to proteolysis [124]. ECM oxidation may also lead to changes in the
assembly and stability of the structure of ﬁbrillary collagens. For
example, collagen III is a homotrimer C-terminally cross-linked by
an inter-chain of three disulﬁde bridges (also known as the cystine
knot) with two adjacent cysteine residues on each of the three a
chains, and these structures are important for the folding and
stability of the molecule [125]. This might be an important me-
chanism involved in the unveiling of auto-antigens in collagen V,
which have been implicated in the pathogenesis of IPF [126].
Oxidants may also result in the shedding of ECM components and/
or the generation of ECM protein fragments with chemotactic
activity. In vivo studies have shown that lung hyaluronan and
heparan sulfates are cleaved by superoxides, while related redox
mechanisms affect the distribution of syndecan-1 [127,128]. Of
course, not all oxidative modiﬁcations of ECM proteins are detri-
mental and some may have physiological roles in wound healing
and other processes. For example, oxidative modiﬁcations of ECM
proteins can lead to covalent cross-linkages which stabilize the
supramolecular structure of the ECM [129].
Thus, ECM proteins can be modiﬁed by MMP-dependent clea-
vage or by oxidation. Interestingly, there is a mechanistic link
between these two pathways since reactive oxidant species can
cleave and activate MMPs. Oxidized glutathione can oxidize
MMPs, thereby inducing their activation, while concomitantly re-
pressing TIMP gene transcription. In normal myocardium, latent
MMPs are activated during end-stage heart failure through oxi-
dized glutathione [130].6. Modulation of redox by ECM
Attention has recently turned to the ability of ECM proteins to
modulate redox reactions. In SV40 MES 13 murine mesangial cells
cultured on collagen type I, the cells produced more reactive
oxidant species and less intracellular nitric oxide when compared
to cells cultured on the basement membrane component collagen
IV, thereby suggesting that the composition of the ECM can
modulate the redox state in the kidney [131]. This is signiﬁcant
considering that diabetic nephropathy is associated with enhanced
collagen I expression. Lung injury is also associated with increased
expression of collagen I and other ﬁbrillar collagens. In other work,
the number of focal adhesions that attach cells to ECM proteins
were found to correlate with age-related slowing down of wound
healing in vitro in skin ﬁbroblasts. This can be modulated by cur-
cumin and appears dependent on modulation of redox reactions
through the induction of the transcription factor Nrf-2 and he-
meoxygenase-1 [132]. Nrf2 is a leucine zipper protein that reg-
ulates the expression of antioxidant proteins and is considered a
protective mechanism in the pathogenesis of pulmonary ﬁbrosis,
although this requires formal proof [133]. Interestingly, hyaluronic
acid upregulates the expression of Nrf2 in chondrocytes via Akt
phosphorylation [134]. Finally, ECM regulated H2O2 consumption
in endothelial cells via regulation of glutathione peroxidase ac-
tivity [135].
The above studies suggest that there is interplay between redox
reactions and the ECM with each modulating the other. Control-
ling these events to prevent, inhibit or, at least, ameliorate ﬁ-
brogenesis in the lung will require a better understanding of these
interactions.
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Cells interact with the ECM via cell surface receptors called
integrins, a family of cell–cell and cell–matrix binding trans-
membrane receptors capable of signal transduction. Integrins are
among the most abundant cell surface receptors and are expressed
in all cell types [136]. In mammals, the integrin receptor family
consists of 18 alpha (α) and 8 beta (β) subunits that link non-
covalently in at least 24 known combinations of αβ subunit het-
erodimers [4,137]. Upon binding, integrins cluster at the cell sur-
face into focal adhesion complexes where they are joined by
several adapter and signaling molecules, thereby establishing a
reversible signaling structure. Downstream signals include tyr-
osine kinase activation, calcium inﬂux, pH changes, and induction
of transcription factors, among others, ultimately leading to dif-
ferential gene expression (Fig. 3). These events control funda-
mental cellular processes such as adhesion, migration, and differ-
entiation, in addition to more coordinated tissue behaviors needed
for adequate morphogenesis and wound healing.
High concentrations of reactive oxygen species have been
found located to focal adhesion complexes where integrins cluster
after ligand binding in ﬁbroblasts and other cells [138]; these re-
gions are considered ‘redox hotspots’. These hotspots reverse soon
after cell–matrix contacts are established suggesting that reactive
oxygen species production and concomitant protein oxidation is
regulated in an ECM adhesion-dependent manner [139].
The ligand-binding activity of integrins can be affected by re-
dox reactions as reported for the integrins α4β1 and α4β7, and
this appears due to free cysteine thiol groups present in both α
and β subunits that are targeted by reactive oxygen species [140].
These events affect leukocyte diapedesis and similar mechanisms
affect platelet aggregation via oxidation of redox-sensitive thiol
residues present in the integrin αΙΙβ/β3 [141]. In adherent cells,
inhibition of matrix contacts triggers reactive oxygen species
production and this is likely due to a decrease in the uptake of
nutrients and the decrease in pyruvate dehydrogenase kinases,
thereby decreasing ATP generation [142].
While the α subunits of integrins contain few cysteine residues,
β subunits are rich in such cysteine residues [143]. Thus, thiol-
related redox reactions can impact integrin conformation, activa-
tion and, therefore, regulate important functions. These events are
important as highlighted by experiments showing that redox-de-
pendent cleavage of the β2 subunit is required for integrin acti-
vation [144]. Hydrogen peroxide induces modiﬁcations in several
cysteines present in the α7 subunit of the integrin α7β1, a laminin
receptor, resulting in conformational changes leading to integrin
activation [145]. Thus, redox modiﬁcations of cysteine residues
within integrin α and β subunits result in conformational changes
capable of promoting signal transduction. These redox-related
changes modulate signals transmitted by the ECM, thereby having
important implications for the cell–matrix interactions and their
roles in tissues.8. Implications
The above observations indicate that redox reactions modulate
ECM production, modiﬁcation, and turnover as well as their re-
cognition and control of cell functions through integrin activation.
Equally interesting are observations suggesting that ECM-integrin
binding can modulate redox reactions, thereby unveiling an in-
terplay between these processes. It is evident that these me-
chanisms are necessary for maintaining cell and tissue home-
ostasis and, therefore, their alteration is likely to play signiﬁcant
roles in diseased states. In particular, uncontrolled redox reactions
are likely relevant in the pathogenesis of tissue ﬁbrosis. It is forthis reason that investigators have attempted to intervene in these
events in disorders including IPF. One such intervention relates to
the delivery of anti-oxidants with the intention of restoring the
oxidant-antioxidant balance, an intervention shown to be feasible
in several studies. For example, intravenous administration of
N-acetylcysteine in subjects with IPF increased GSH levels in al-
veolar lining ﬂuid [146]. In this work, the authors found that, at
baseline, the levels of total GSH in IPF subjects were higher than in
controls. This highlights the problems inherent with the reliance
on measuring total GSH levels alone for determining antioxidant
capacity in lung. The effects of oral N-acetylcysteine on lung GSH
levels in IPF has been tested and these studies revealed a sig-
niﬁcant increase in GSH in bronchoalveolar lavage ﬂuid [147].
When testing the effects of GSH aerosol in 10 patients with IPF,
investigators showed increased GSH levels in the epithelial cell
lining ﬂuid as well as a decrease in spontaneous superoxide anion
release by alveolar macrophages [148]. More recently, in-
vestigators tested the therapeutic effects of N-acetylcysteine in a
cohort of patients with IPF; that study revealed a beneﬁcial effect,
which prompted the almost widespread use of N-acetylcysteine, in
combination with other drugs, in the treatment of IPF [149].
However, a large, randomized, placebo-controlled study was hal-
ted early when an interim analysis revealed that IPF patients re-
ceiving a combination of prednisone, azathioprine, and NAC had
an increased rate of death and hospitalizations [150]. Another
component of that study was to study the effectiveness of NAC
alone against placebo, and that arm of the study was allowed to
continue. That study revealed that NAC alone did not prove ben-
eﬁcial. More recently, genetic studies suggested that NAC could be
helpful in a subset of patients carrying a single nucleotide poly-
morphism in the TOLLIP gene, but this has not been tested pro-
spectively [151]. The kinetics of N-acetylcysteine and its relatively
narrow effect may have thwarted its impact in that particular trial.
Pirfenidone is an exciting new drug for the treatment of IPF [152].
It has been suggested that it acts as an antioxidant, but the evi-
dence for this is not very strong. In vitro assays showed that pir-
fenidone could scavenge hydroxyl radicals but not superoxide or
hydrogen peroxide [152,153]. Independent of this, the data im-
plicating redox reactions in the pathogenesis of IPF are so strong
that few are willing to dismiss the possibility that more effective
interventions capable of affecting these reactions via distinct
mechanisms of action may emerge in the not-to-distant future
[154,155].
In the meantime, others have begun to evaluate the possible
detection of oxidative modiﬁed proteins in the plasma of human
subjects as potential biomarkers of redox reactions in lung disease.
In this regard, oxidative modiﬁcations of protein tyrosyl residues
were found to be increased in the plasma of subjects with inter-
stitial lung disease [156]. Biomarkers of oxidative stress may ulti-
mately have prognostic implications with regards to disease
course or responsiveness to treatment, but considering that oxi-
dative stress is common in chronic respiratory disorders, they will
not likely play a diagnostic role.
It must be acknowledged that, although this document focuses
on the lung ﬁbroblast, other studies point to the importance of
epithelial and endothelial cells, among others, in pulmonary ﬁ-
brosing disorders [157]. ROS production and the involvement of
Nox-1 and Nox-4 in mediating ﬁbrogenic effects through epithelial
and endothelial cell death have been reported [158,159]. In fact,
blockade of epithelial cell apoptosis induced by bleomycin in Nox-
4 deﬁcient mice is protective [159].
In short, ECM proteins are considered important players in
processes responsible for lung development, injury and repair, and
abnormalities in their expression, turnover, and recognition re-
present potential targets for intervention in chronic ﬁbrosing lung
disorders. Considering that redox reactions play roles in each of
Table 1
Examples of potential targets for intervention based on phenotype observed in the
bleomycin model.
Intervention Bleomycin-induced phenotype Ref.
EC-SOD knockdown Increased ﬁbrosis, inﬂammation, and oxidative
protein fragmentation
[161]
Nox-4 knockdown Decreased ﬁbrosis, reduced accumulation of
myoﬁbroblasts
[159]
P47phox knockdown Absence of collagen deposition, increased
inﬂammation
[93]
Nrf knockdown Increased ﬁbrosis [25]
Smad3knockdown Decreased ﬁbrosis [162]
FN EDA knockdownn Decreased ﬁbrosis [47]
β6 integrin knockdown Decreased ﬁbrosis, increased inﬂammation [163]
nFN: ﬁbronectin.
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such interactions are likely to unveil novel insights into disease
pathogenesis. This research is already unveiling molecules and
pathways that could be targeted to reduce the burden of pul-
monary ﬁbrosing disorders (Table 1).Acknowledgments
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